Heron Therapeutics, Inc. (HRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.34+4.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HRTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 151.2 | 154.9 | 144.3 | 127.0 | 107.7 | 86.3 | 88.6 | 146.0 | 77.5 | 30.8 | 1.3 | — | — | — | — | — |
| Cost of Revenues | 45.2 | 41.3 | 38.6 | 65.1 | 54.9 | 46.0 | 36.2 | 61.6 | 27.5 | — | — | — | — | — | — | — |
| Gross Profit | 105.9 | 113.6 | 105.6 | 61.9 | 52.8 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 12.3 | 12.4 | 16.7 | 39.1 | 82.7 | 130.8 | 174.5 | 167.4 | 140.0 | 138.6 | 103.1 | 61.2 | 54.8 | 32.5 | 15.2 | 8.2 |
| Operating Income | (10.9) | (2.5) | (11.5) | (110.6) | (174.7) | (217.8) | (228.2) | (210.7) | (183.9) | (194.6) | (170.9) | (96.9) | (74.6) | (54.5) | (23.8) | (11.1) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 9.6 | 6.0 | 3.9 | 2.5 | 2.4 | 1.9 | 1.5 | 2.7 | 3.9 | 2.7 | 1.0 | 0.9 | — | — | — |
| Interest & Investment Income | — | 1.9 | 3.6 | 3.4 | 1.6 | 0.4 | 3.6 | 7.3 | 6.0 | 1.0 | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | 0.5 | 0.8 | 2.0 | (1.7) | (5.8) | (3.3) | 2.9 | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | — | (17.7) | (2.1) | 0.1 | (7.4) | (2.9) | 0.9 | 5.9 | 5.1 | (2.9) | (2.2) | (0.7) | (1.8) | — | — | — |
| Asset Writedown | — | — | — | 0.6 | 0.2 | 0.5 | 0.8 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.9 | — | — | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (11.4) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | (0.1) |
| Net Income | ||||||||||||||||
| Net Income | (33.9) | (20.2) | (13.6) | (111.0) | (182.0) | (221.0) | (227.3) | (204.7) | (178.8) | (197.5) | (173.1) | (97.6) | (76.4) | (55.3) | (23.3) | (11.8) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.18) | (0.12) | (0.09) | (0.80) | (1.67) | (2.24) | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.18) | (0.12) | (0.09) | (0.80) | (1.67) | (2.24) | — | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 0.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 190.3 | 166.7 | 152.4 | 138.1 | 108.9 | 0.1 | — | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 190.3 | 166.7 | 152.4 | 138.1 | 108.9 | 0.1 | — | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (0.2) | (9.0) | (107.7) | (171.8) | (214.8) | (225.3) | (208.7) | (182.4) | (193.0) | (169.8) | (96.2) | (74.0) | (54.1) | (23.6) | (10.9) |
| EBIT | (10.9) | (2.5) | (11.5) | (110.6) | (174.7) | (217.8) | (228.2) | (210.7) | (183.9) | (194.6) | (170.9) | (96.9) | (74.6) | (54.5) | (23.8) | (11.1) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.